Agree on almost all that with various plan Bs. Specifically regarding containment verification, a plan B would be different approach that yields verification FDA wants should the rabbits prove to be a dead end. It's a moot point if JHU rabbit tumors reach sufficient size before meeting, but I'd be prepared to discuss other options at meeting with FDA if Rabbit model remains doubtful at that time. I sure hope MK goes to meeting prepared cuz time is of the essence.
Regarding IsoPet becoming profitable as a plan B: would be great if RDGL had resources to pull it off before next offering needed, but that looks very unlikely. Without IDE at least submitted before next offering, things get ugly. It is what it is.
News 
Market Data 
Discover 
